These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38099867)

  • 1. Prevention of moderate and severe ovarian hyperstimulation syndrome: a guideline.
    Practice Committee of the American Society for Reproductive Medicine. Electronic address: asrm@asrm.org
    Fertil Steril; 2024 Feb; 121(2):230-245. PubMed ID: 38099867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline.
    ;
    Fertil Steril; 2016 Dec; 106(7):1634-1647. PubMed ID: 27678032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ovarian hyperstimulation syndrome: a preventable syndrome?
    Rosenwaks Z; Benadiva C
    Semin Reprod Med; 2010 Nov; 28(6):437-9. PubMed ID: 21082500
    [No Abstract]   [Full Text] [Related]  

  • 4. The prevention of ovarian hyperstimulation syndrome.
    Corbett S; Shmorgun D; Claman P; ;
    J Obstet Gynaecol Can; 2014 Nov; 36(11):1024-1033. PubMed ID: 25574681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of ovarian hyperstimulation syndrome.
    Wiwanitkit V
    Fertil Steril; 2011 Jun; 95(8):e65; author reply e66. PubMed ID: 21530962
    [No Abstract]   [Full Text] [Related]  

  • 6. Ovarian hyperstimulation syndrome. A new look at an old problem.
    Petrenko AP; Castelo-Branco C; Marshalov DV; Salov IA; Shifman EM
    Gynecol Endocrinol; 2019 Aug; 35(8):651-656. PubMed ID: 30935259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine agonist bromocriptine for the prevention of ovarian hyperstimulation syndrome.
    Spitzer D; Wogatzky J; Murtinger M; Zech MH; Haidbauer R; Zech NH
    Fertil Steril; 2011 Jun; 95(8):2742-4.e1. PubMed ID: 21411081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Intensive therapy of ovarian hyperstimulation syndrome (clinical guidelines)].
    Kulikov AV; Shifman EM; Portnov IG
    Anesteziol Reanimatol; 2015; 60(1):73-6. PubMed ID: 26027232
    [No Abstract]   [Full Text] [Related]  

  • 9. Blood group and ovarian hyperstimulation syndrome.
    Bellver J; Ferrando M; Garrido N; Pellicer A
    Fertil Steril; 2010 Jan; 93(1):270-1. PubMed ID: 19683228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progestogens for prevention of luteinising hormone (LH) surge in women undergoing controlled ovarian hyperstimulation as part of an assisted reproductive technology (ART) cycle.
    Glujovsky D; Pesce R; Miguens M; Sueldo C; Ciapponi A
    Cochrane Database Syst Rev; 2023 Nov; 11(11):CD013827. PubMed ID: 38032057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whether Letrozole could reduce the incidence of early ovary hyperstimulation syndrome after assisted reproductive technology? A systematic review and meta-analysis.
    Zhao J; Xu B; Huang X; Yan Y; Li Y
    Reprod Health; 2020 Nov; 17(1):181. PubMed ID: 33218353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do dopamine agonists prevent or reduce the severity of ovarian hyperstimulation syndrome in women undergoing assisted reproduction? A systematic review and meta-analysis.
    Baumgarten M; Polanski L; Campbell B; Raine-Fenning N
    Hum Fertil (Camb); 2013 Sep; 16(3):168-74. PubMed ID: 24047196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clomiphene combined with gonadotropins and GnRH antagonist versus conventional controlled ovarian hyperstimulation without clomiphene in women undergoing assisted reproductive techniques: systematic review and meta-analysis.
    Figueiredo JB; Nastri CO; Vieira AD; Martins WP
    Arch Gynecol Obstet; 2013 Apr; 287(4):779-90. PubMed ID: 23250342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention and management of ovarian hyperstimulation syndrome.
    Nelson SM
    Thromb Res; 2017 Mar; 151 Suppl 1():S61-S64. PubMed ID: 28262238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Use of cabergoline for prevention of ovarian hyperstimulation syndrome in assisted reproductive technologies].
    Kozovski G; Angelova M; Kacarova P
    Akush Ginekol (Sofiia); 2014; 53(5):34-5. PubMed ID: 25558669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovarian hyperstimulation syndrome associated with clomiphene citrate.
    Mitchell SY; Fletcher HM; Williams E
    West Indian Med J; 2001 Sep; 50(3):227-9. PubMed ID: 11769032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of letrozole on moderate and severe early-onset ovarian hyperstimulation syndrome in high-risk women: a prospective randomized trial.
    Mai Q; Hu X; Yang G; Luo Y; Huang K; Yuan Y; Zhou C
    Am J Obstet Gynecol; 2017 Jan; 216(1):42.e1-42.e10. PubMed ID: 27555316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cabergoline for the prevention of ovarian hyperstimulation syndrome: systematic review and meta-analysis of randomized controlled trials.
    Leitao VM; Moroni RM; Seko LM; Nastri CO; Martins WP
    Fertil Steril; 2014 Mar; 101(3):664-75. PubMed ID: 24360566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting and preventing ovarian hyperstimulation syndrome (OHSS): the need for individualized not standardized treatment.
    Fiedler K; Ezcurra D
    Reprod Biol Endocrinol; 2012 Apr; 10():32. PubMed ID: 22531097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Towards complication-free assisted reproduction technology.
    Santos-Ribeiro S; Mackens S; Racca A; Blockeel C
    Best Pract Res Clin Endocrinol Metab; 2019 Feb; 33(1):9-19. PubMed ID: 30473208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.